Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Qnexa

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Obesity, the primary health threat in the 21st century, affects the quality of life physiologically, economically and… Expand
  • table 1
  • table 2
Is this relevant?
2012
2012
An antiobesity medication called “Qnexa” (a combination of phentermine and topiramate) lead to 10% weight loss in obese adults in… Expand
Is this relevant?
Review
2011
Review
2011
The medical management of pituitary tumors is entering a new era. Novel compounds that directly target the pituitary tumor have… Expand
  • figure 1
Is this relevant?
2011
2011
126 www.thelancet.com Vol 378 July 9, 2011 3 Vivus. FDA issues complete response letter to Vivus regarding new drug application… Expand
Is this relevant?
2011
2011
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical… Expand
Is this relevant?
2011
2011
Vivus has resubmitted its New Drug Application (NDA) for Qnexa (phentermine/topiramate) to FDA. 
Is this relevant?
2010
2010
  • Dan Jones
  • Nature Reviews Drug Discovery
  • 2010
  • Corpus ID: 20944041
Despite high safety hurdles and a history of failure in the field, some drug firms remain cautiously optimistic for the next wave… Expand
  • table 1
Is this relevant?
2010
2010
In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity… Expand
Is this relevant?
2009
2009
  • Dan Jones
  • Nature Reviews Drug Discovery
  • 2009
  • Corpus ID: 32904312
Phase III trial results for three anti-obesity therapies suggest that they meet at least some of the efficacy benchmarks for… Expand
  • table 1
Is this relevant?
2008
2008
Obesity is a major public health problem. For many obese patients, diet and exercise are an inadequate treatment and bariatric… Expand
Is this relevant?